FY2024 EPS Estimates for enGene Raised by Leerink Partnrs

enGene Holdings Inc. (NASDAQ:ENGN) – Analysts at Leerink Partnrs upped their FY2024 earnings estimates for enGene in a report released on Wednesday, October 30th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($1.42) per share for the year, up from their previous forecast of ($1.48). The consensus estimate for enGene’s current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for enGene’s Q4 2024 earnings at ($0.32) EPS, FY2025 earnings at ($1.43) EPS, FY2026 earnings at ($2.55) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.64) EPS.

A number of other analysts also recently weighed in on ENGN. Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $40.00 target price on shares of enGene in a research note on Wednesday, September 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, enGene currently has an average rating of “Buy” and an average target price of $33.67.

enGene Stock Up 0.5 %

Shares of ENGN stock opened at $8.89 on Friday. The business’s fifty day moving average is $7.33 and its 200 day moving average is $9.28. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene has a twelve month low of $4.42 and a twelve month high of $27.99.

enGene (NASDAQ:ENGN) last posted its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05.

Institutional Trading of enGene

Institutional investors have recently made changes to their positions in the stock. Altitude Crest Partners Inc. bought a new position in enGene during the first quarter valued at approximately $2,039,000. SR One Capital Management LP bought a new position in shares of enGene during the 2nd quarter valued at $4,715,000. Logos Global Management LP boosted its stake in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in shares of enGene in the first quarter worth $17,095,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

Insider Activity at enGene

In other news, major shareholder Growth Opportunities F. Forbion bought 5,997 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were purchased at an average price of $6.54 per share, for a total transaction of $39,220.38. Following the completion of the purchase, the insider now owns 2,457,989 shares in the company, valued at approximately $16,075,248.06. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other enGene news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the stock in a transaction dated Friday, September 27th. The shares were purchased at an average cost of $5.70 per share, with a total value of $57,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares in the company, valued at $57,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion bought 5,997 shares of the firm’s stock in a transaction on Friday, October 4th. The stock was acquired at an average cost of $6.54 per share, with a total value of $39,220.38. Following the transaction, the insider now owns 2,457,989 shares in the company, valued at $16,075,248.06. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 420,965 shares of company stock valued at $2,651,103. 13.70% of the stock is owned by insiders.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.